819 results on '"Thomas, Roman K."'
Search Results
2. Evolutionary trajectories of small cell lung cancer under therapy
3. CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 HeterodimerizationCD74-NRG1 Gene Fusion as a Bona Fide Oncogene
4. Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer
5. Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer
6. Chromothripsis followed by circular recombination drives oncogene amplification in human cancer
7. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.
8. Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities
9. A Tuft Cell–Like Signature Is Highly Prevalent in Thymic Squamous Cell Carcinoma and Delineates New Molecular Subsets Among the Major Lung Cancer Histotypes
10. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors
11. A mechanistic classification of clinical phenotypes in neuroblastoma
12. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
13. Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes
14. Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer
15. Texture analysis of iodine maps and conventional images for k-nearest neighbor classification of benign and metastatic lung nodules
16. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer
17. Comprehensive genomic profiles of small cell lung cancer
18. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
19. Correction to: Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis
20. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
21. Table S7 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
22. Supplementary Data from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
23. Data from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
24. Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens
25. Depletion of histone methyltransferase KMT9 inhibits lung cancer cell proliferation by inducing non-apoptotic cell death
26. Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain.
27. Table S2 from Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
28. Supplementary Figures S1 to S12 from Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
29. Data from Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
30. Supplementary Figure from CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
31. Data from CD74–NRG1 Fusions in Lung Adenocarcinoma
32. Supplementary Data from CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
33. Data from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
34. Data from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
35. Interview with Dr. Meyerson from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
36. Supplementary text from Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
37. Supplementary Tables from CD74–NRG1 Fusions in Lung Adenocarcinoma
38. Supplementary Methods and Legends from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
39. Data from Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
40. Supplementary Figure Legends 1-7 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
41. Supplementary Figures 1-7 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
42. Supplementary Tables S3-S8 from Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
43. Supplementary Table 1 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
44. Supplementary Figures S1-S14 from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
45. Supplementary Figures 1-11 from Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
46. Supplementary Figures from CD74–NRG1 Fusions in Lung Adenocarcinoma
47. Supplementary Figure 3 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
48. Data from ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
49. Supplementary Data from Blood-Based Gene Expression Signatures in Non–Small Cell Lung Cancer
50. Supplementary Table S2 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.